Genetic variation in the LMP/TAP gene and outcomes of hepatitis B virus infection in the Chinese population

Epidemiology and Infection

Volumn 139, Issue 5, 2011, Pages 674-682

  Shi, C ^a   Qian, Y H ^b   Su, J ^a   Luo, S S ^a   Gu, J ^b   You, H ^a   Cui, Q ^a   Lin, Y D ^b   Dong, M H ^b   Yu, R B ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Wuxi Center for Disease Control and Prevention   (China)

Author keywords

Hepatitis B virus; infection; LMP TAP gene; outcome; polymorphism

Indexed keywords

GENOMIC DNA;

ADULT; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HAPLOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOTE DETECTION; HUMAN; INTERMETHOD COMPARISON; LOW MOLECULAR WEIGHT POLYPEPTIDE GENE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREVALENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSPORTER WITH ANTIGEN PROCESSING GENE; VIRUS GENE; ANTIGEN PRESENTATION; ASIAN; CHINA; GENETICS; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ANTIGEN PRESENTATION; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; FEMALE; GENE FREQUENCY; GENETIC VARIATION; HAPLOTYPES; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TREATMENT OUTCOME;

EID: 79957718328     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268810001299     Document Type: Article

References (35)

1. Luo J, et al. Meta-analysis on the relationship between HLA-DRB1 gene polymorphism and chronic hepatitis B in Chinese population. World Chinese Journal of Digestology 2006; 14: 3050-3054. (Pubitemid 46112713)
2. Qian YH, et al. Review of the relationship between HLA-DR, DQ genes and chronic hepatitis B. Modern Preventive Medicine 2009; 36: 131-133.
3. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annual Review of Immunology 1996; 14: 369-396. (Pubitemid 26130189)
4. Heemels MT, Ploegh H. Generation, translocation, and presentation of MHC class I-restricted peptides. Annual Review of Biochemistry 1995; 64: 463-491.
5. Driscoll J, et al. MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature 1993; 365: 262-264. (Pubitemid 23282086)
6. Gaczynska M, Rock KL, Goldberg AL. Gammainterferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 1993; 365: 264-267. (Pubitemid 23282087)
7. Neefjes JJ, Momburg F, Hammerling GJ. Selective and ATP-dependent translocation of peptides by the MHCencoded transporter. Science 1993; 261: 769-771. (Pubitemid 23278394)
8. Shepherd JC, et al. TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell 1993; 74: 577-584. (Pubitemid 23244622)
9. Cromme FV, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. Journal of Experimental Medicine 1994; 179: 335-340. (Pubitemid 24013001)
10. Seliger B, Maeurer MJ, Ferrone S. TAP off-tumors on. Immunology Today 1997; 18: 292-299.
11. Cao B, et al. LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China. Carcinogenesis 2005; 26: 1280-1284. (Pubitemid 41417906)
12. McTernan CL, et al. Assessment of the non-HLADR- DQ contribution to IDDM1 in British Caucasian families : analysis of LMP7 polymorphisms. Diabetic Medicine 2000; 17: 661-666.
13. Prahalad S, et al. Polymorphism in the MHC-encoded LMP7 gene: association with JRA without functional significance for immunoproteasome assembly. Journal of Rheumatology 2001; 28: 2320-2325. (Pubitemid 32947883)
14. Vargas-Alarcon G, et al. Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis. Human Immunology 2004; 65: 1437-1442. (Pubitemid 39643224)
15. Khu YL, et al. Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity. Biochemical Journal 2004; 384: 401-409.
16. Lautscham G, Rickinson A, Blake N. TAP-independent antigen presentation on MHC class I molecules: lessons from Epstein-Barr virus. Microbes and Infection 2003; 5: 291-299. (Pubitemid 36428718)
17. Neumeister C, et al. Measles virus and canine distemper virus target proteins into a TAP-independent MHC class I-restricted antigen-processing pathway. Journal of General Virology 2001; 82: 441-447. (Pubitemid 32123898)
18. Taniuchi S, et al. Polymorphism of Fc gamma RIIa may affect the efficacy of gamma-globulin therapy in Kawasaki disease. Journal of Clinical Immunology 2005; 25: 309-313. (Pubitemid 41204254)
19. Van Belzen MJ, et al. CTLA4+49 A/G and CT60 polymorphisms in Dutch coeliac disease patients. European Journal of Human Genetics 2004; 12: 782-785.
20. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. American Journal of Human Genetics 2001; 68: 978-989. (Pubitemid 32289743)
21. Dai Y, et al. Association between LMP2/LMP7 gene polymorphism and the infection of hepatitis B virus. Journal of Peking University 2005; 37: 508-512.
22. Tang J, et al. Genotyping TAP2 variants in North American Caucasians, Brazilians, and Africans. Genes and Immunity 2001; 2: 32-40. (Pubitemid 33674867)
23. Witkowska-Tobola AM, et al. Polymorphism of the TAP1 gene in Polish patients with psoriasis vulgaris. Journal of Applied Genetics 2004; 45: 391-393. (Pubitemid 39273134)
24. Jung MC, Pape GR. Immunology of hepatitis B infection. Lancet Infectious Diseases 2002; 2: 43-50. (Pubitemid 36109305)
25. Xu C, et al. Genetic polymorphisms of LMP/TAP gene and hepatitis B virus infection risk in the Chinese population. Journal of Clinical Immunology 2007; 27: 534-541. (Pubitemid 47319248)
26. McCluskey J, Rossjohn J, Purcell AW. TAP genes and immunity. Current Opinion in Immunology 2004; 16: 651-659. (Pubitemid 39165894)
27. Obst R, et al. TAP polymorphism does not influence transport of peptide variants in mice and humans. European Journal of Immunology 1995; 25: 2170-2176.
28. Quadri SA, Singal DP. Peptide transport in human lymphoblastoid and tumor cells : effect of transporter associated with antigen presentation (TAP) polymorphism. Immunology Letters 1998; 61: 25-31. (Pubitemid 28161147)
29. Daniel S, et al. Absence of functional relevance of human transporter associated with antigen processing polymorphism for peptide selection. Journal of Immunology 1997; 159: 2350-2357. (Pubitemid 127681027)
30. Sugimoto Y, et al. A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. Journal of Viral Hepatitis 2002; 9: 377-384.
31. Sijts AJ, et al. Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. Journal of Experimental Medicine 2000; 191: 503-514.
32. Judson R, Stephens JC. Notes from the SNP vs. haplotype front. Pharmacogenomics 2001; 2: 7-10. (Pubitemid 32633647)
33. Judson R, Stephens JC, Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics 2000; 1: 15-26.
34. Sun T, et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. Journal of National Cancer Institute 2004; 96: 1030-1036. (Pubitemid 39162646)
35. Zhang X, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. Journal of Medical Genetics 2005; 42: 479-484. (Pubitemid 40847235)